Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818141 · ClinicalTrials.gov registry record · Phase 4
Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
A Phase 4 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT01818141 is a Phase 4 study that has completed, run by Hartford Hospital. The registered enrollment target is 34 participants.
The verdict
NCT01818141, a Phase 4 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to compare number of vegetative cells and spores in stool over time for fidaxomicin or vancomycin in patients diagnosed with their first episode of C. difficile infection.
Interventions
- DRUG Vancomycin
- DRUG Fidaxomicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-10-17 |
| Est. Completion | 2014-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818141
The ClinicalTrials.gov registry entry for NCT01818141 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT01818141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818141 about?
NCT01818141 is a clinical study titled "Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin". The purpose of this study is to compare number of vegetative cells and spores in stool over time for fidaxomicin or vancomycin in patients diagnosed with their first episode of C. difficile infection.
What is the current status of trial NCT01818141?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2012-10-17. Estimated completion is 2014-12-15.
What interventions are being tested in trial NCT01818141?
The interventions under investigation include: Vancomycin (DRUG), Fidaxomicin (DRUG).
Who is sponsoring clinical trial NCT01818141?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.